Hagop M. Kantarjian
University of Texas MD Anderson Cancer Center
4152 Papers
32.7K Citations
Hagop M. Kantarjian is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 204, co-authored 3708 publications. Previous affiliations of Hagop M. Kantarjian include Rice University & University of Chicago.
Chat about Author
Papers
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial
Tapan M. Kadia,Jorge E. Cortes,Farhad Ravandi,Elias Jabbour,Marina Konopleva,Christopher B. Benton,Jan A. Burger,Koji Sasaki,Gautam Borthakur,Courtney D. DiNardo,Naveen Pemmaraju,Naval Daver,Alessandra Ferrajoli,Xuemei Wang,Keyur P. Patel,Jeffrey L. Jorgensen,Sa Wang,Susan O'Brien,Sherry Pierce,Carla Tuttle,Zeev Estrov,Srdan Verstovsek,Guillermo Garcia-Manero,Hagop M. Kantarjian +23 more
TL;DR: The combination of cladribine and low-dose cytarabine alternating with decitabine appears to be a safe and highly effective regimen for the treatment of elderly or unfit patients with newly diagnosed AML.
119
Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia
Apostolia Maria Tsimberidou,Constantine S. Tam,Lynne V. Abruzzo,Susan O'Brien,William G. Wierda,Susan Lerner,Hagop M. Kantarjian,Michael J. Keating +7 more
TL;DR: An 11q22 deletion is considered an independent factor predicting poor survival in chronic lymphocytic leukemia (CLL).
119
Acute Promyelocytic Leukemia: A Population-Based Study on Incidence and Survival in the United States, 1975 – 2008
TL;DR: A population‐based study of APL in the United States to determine its incidence and relative survival during a 34‐year period.
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
Francis J. Giles,Elisabetta Abruzzese,Giovanni Rosti,Dong-Kee Kim,Ravi Bhatia,A. Bosly,Stuart L. Goldberg,G. L.S. Kam,Madan Jagasia,W. Mendrek,Thomas Fischer,Thierry Facon,U. Dünzinger,David Marin,Martin C. Mueller,Yaping Shou,Neil Gallagher,Richard A. Larson,Mahon Fx,Michele Baccarani,Jorge E. Cortes,Hagop M. Kantarjian +21 more
TL;DR: Nilotinib is an effective therapy in C ML-CP and -AP following failure of both imatinib and dasatinib therapy, and the estimated 18-month survival rate in CML-CP was 86% and that at 12 months for CML -AP was 80%.
119
Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance
Wenyong Zhang,Jorge E. Cortes,Hui Yao,Li Zhang,Neelima Reddy,Elias Jabbour,Hagop M. Kantarjian,Dan Jones +7 more
TL;DR: Gene expression profiling of CML at diagnosis for PTGS1 may be useful in predicting imatinib response and in selecting alternate therapy.
119